1

	-			
1	Anti-cardiolipin and other anti-phospholipid antibodies in critically ill COVID-19 positive and			
2	negative patients			
3				
4	Uriel Trahtemberg MD, PhD ¹ ; Robert Rottapel MD ^{2,3} ; Claudia C dos Santos MD ^{1,4,5} ; Arthur S.			
5	Slutsky, MD ^{4,5} ; Andrew J Baker MD ^{1,4,5} ; Marvin J Fritzler MD, PhD* ⁶ on behalf of the COVID19			
6	Longitudinal Biomarkers of Lung Injury (COLOBILI) group.			
7				
8	^{1.} Critical Care Department, St. Michael's Hospital, Toronto, ON, Canada.			
9	^{2.} Departments of Medicine and Immunology, University of Toronto, Toronto, ON, Canada.			
10	^{3.} Division of Rheumatology, St. Michael's Hospital, Toronto, ON, Canada.			
11	^{4.} Keenan Centre for Biomedical Research, Li Ka Shing Knowledge Institute, St. Michael's			
12	Hospital, Toronto, ON, Canada.			
13	^{5.} Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON,			
14	Canada			
15	^{6.} Cumming School of Medicine, University of Calgary, Calgary, AB Canada.			
16				
17	* Corresponding author:			
18	Marvin J. Fritzler PhD MD			
19	Cumming School of Medicine			
20	University of Calgary			
21	3330 Hospital Dr. NW			
22	Calgary, AB, Canada T2N 4N1			
23	Email: fritzler@ucalgary.ca			
24	Telephone: +01-403-220-3533			
25 26	ORCID ID: 0000-0003-1652-6608			
27	Abstract word count: 197			
28	Manuscript word count: 1493			
29	References: 20			
30	Figures & Tables: 3			

31 Supplemental Tables: 3

2

33 ABSTRACT

- 34 Background: Reports of severe COVID-19 being associated with thrombosis, anti-phospholipid
- 35 antibodies (APLA), anti-phospholipid syndrome (APS) have yielded disparate conclusions.
- 36 Studies comparing COVID-19 patients with contemporaneous controls of similar severity are
- 37 lacking.
- 38 Methods: 22 COVID⁺ and 20 COVID⁻ patients with respiratory failure admitted to intensive care
- 39 were studied longitudinally. Demographic and clinical data were obtained from the day of
- 40 admission. APLA testing included anti-cardiolipin (aCL), anti- β 2glycoprotien 1 (β 2GP1), anti-
- 41 domain 1 beta2 glycoprotein 1 (β2GP1) and anti-phosphatidyl serine/prothrombin complex
- 42 (PS/PT). Anti-nuclear antibodies (ANA) were detected by immunofluorescence and antibodies to
- 43 cytokines by a commercially available multiplexed array. ANOVA was used for continuous
- 44 variables and Fisher's exact test was used for categorical variables with α =0.05 and the false
- discovery rate at q=0.05.
- 46 Results: APLA were predominantly IgG aCL (48%) followed by IgM (21%) in all patients, with a
- 47 tendency toward higher frequency among the COVID⁺. aCL was not associated with surrogate
- 48 markers of thrombosis but IgG aCL was strongly associated with worse disease severity and
- 49 higher ANA titers regardless of COVID-19 status. An association between aCL and anti-cytokine
- 50 autoantibodies tended to be higher among the COVID⁺.
- 51 Conclusions: Positive APLA serology was associated with more severe disease regardless of
- 52 COVID-19 status.
- 53
- 54 **KEYWORDS:** Antiphospholipid; anticardiolipin; COVID-19; critical care; lung injury.
- 55
- 56

57 INTRODUCTION

Anti-phospholipid antibodies (APLA) are biomarkers of a spectrum of clinical features observed
in anti-phospholipid syndrome (APS) ¹. Features of APS include venous and arterial thrombosis
involving multiple organs and having various presentations ¹. APLA that are components of APS
criteria include IgG and/or IgM anti-cardiolipin (aCL), -β2-glycoprotein1 (GP1), and the "lupus
anticoagulant" (LAC)². Other non-criteria APLA such as anti-phosphatidylserine/prothrombin
(PS/PT) complex, -PT, and -domain 1 of β2-GP1 have also found a diagnostic niche in APS³⁴.
One of the salient features of COVID-19 is the development of thrombotic events associated

- 66 with severe morbidity and mortality 5-8. In the context of systemic inflammation and
- 67 dysregulated immunity⁹, some reports have linked APLA to these thromboses ¹⁰¹¹, severe
- 68 COVID-19^{5 12} and release of neutrophil extracellular traps⁵. However, APLA are also described in
- 69 a variety of other infectious diseases¹³ and critically ill patients have high rates of
- thromboembolism that were not linked to APS or APLA¹⁴. Therefore, the association of COVID-
- 71 19 with APLA and their potential pathogenic role ¹⁵ has not been clearly demonstrated due to
- the lack of contemporaneous, COVID-19 negative controls. Here we compare the prevalence
- and clinical correlations of APLA in patients with severe COVID-19 as compared to
- 74 contemporaneous non-COVID19 patients with similar clinical characteristics.
- 75

76 METHODS

77 This is an observational cohort study of patients admitted to St. Michael's Hospital (Toronto, 78 ON, Canada), as approved by the Research Ethics Board (REB# 20-078). Informed consent was 79 obtained from all patients or their legal surrogates. Inclusion criteria were age ≥18 years, 80 admission to intensive care unit (ICU) with acute respiratory failure. Exclusion criteria were 81 inability to ascertain the primary outcome or obtain a baseline blood sample, and SARS-CoV2 infection in the 4 weeks prior to admission. COVID-19 status was determined with PCR of 82 83 nasopharyngeal swabs and/or endotracheal aspirates. Follow-up was 3 months post-ICU 84 admission or hospital discharge. Primary outcome was death in the ICU. Secondary outcomes were in hospital-death, ICU utilization metrics, organ dysfunction measures and severity scores. 85 86 Clinical data and serum samples were collected longitudinally at days 0, 1, 3, 5, 7 and 10; after 87 day 10 or ICU discharge. Anti-CL, anti- β 2-GP1 and anti-PS/PT were tested for IgG and IgM, as 88 well as IgG anti-domain 1 β2-GP1; all by ELISA or chemiluminescence (Inova Diagnostics, San

4

Diego, CA USA). ANOVA was used for continuous variables and Fisher's exact test was used for
categorical variables at α=0.05, followed by a false discovery rate adjustment at q=0.05. Detailed
methods are available (online supplement), including methods for detection of anti-nuclear
autoantibodies (ANA) by HEp-2 immunofluorescence assay (IFA) (Inova Diagnostics, San Diego,
CA USA), and antigen-specific autoantibodies (TheraDiag, Paris, France) and anti-cytokine
autoantibodies (Millipore, Oakville, ON, Canada) using addressable laser bead immunoassays.

96 **RESULTS**

97 The demographic and clinical parameters of 22 COVID-19 positive (COVID⁺) and 20 COVID-19

98 negative (COVID⁻) patients (Table 1) included an average of 14.1 day stays in ICU and 31%

99 mortality, but no statistically significant differences between the two cohorts, including the lack

100 of significant differences in the number of thrombotic events requiring therapeutic

101 anticoagulation, platelet counts, or platelet counts normalized to the neutrophil counts (to index

102 for severity) (Table 1). None of the patients had a history of antecedent APS, systemic lupus

- 103 erythematosus (SLE) or other conditions associated with APS, nor were there significant
- 104 differences in other past medical history between COVID⁺ and COVID⁻ patients (supplemental

105 table 1).

106

107 Frequency, development and distribution of aCL. Forty-eight percent of all the ICU cohort had a 108 positive IgG aCL test (Table 1); interestingly, fewer patients had elevated titers of IgM aCL (n=9, 109 21%), with only 2 patients having IgM without IgG. Although more COVID⁺ had aCL antibodies, 110 the difference was not statistically significant. Longitudinally testing for anti-β2-GP1 and anti-111 PS/PT for IgG and IgM, as well as domain 1 β 2-GP1 IgG revealed only one patient (COVID⁺) with 112 positive serology for any of these autoantibodies. This patient seroconverted to IgM anti-PS/PT 113 at days 5-7 of ICU hospitalization. Table 2 shows the temporal development of the aCL IgG and 114 IgM antibodies stratified by COVID status. Late appearing (beyond 10 days after admission) aCL 115 antibodies were not included in the statistical analyses to avoid survival and availability bias. 116 Anti-CL were not associated with age or sex (not shown).

117

aCL vs disease severity, platelet counts and need for anticoagulation. Patients positive for aCL
 IgG demonstrated a consistent trend for worse outcomes in all the measures tested but this did

5

not reach statistical significance after adjusting for multiple comparisons (Table 3). These trends
remained when analyzed separately for COVID⁺ and COVID⁻ (not shown). Anti-CL IgG positive
patients showed no significant differences in platelet counts, platelet to neutrophil ratio or the
need for therapeutic anticoagulation (Table 3).

124

125 aCL association with ANA, antigen-specific autoantibodies and anti-cytokine autoantibodies. 126 Although aCL IgG positivity was not associated with the presence of HEp-2 IFA ANA at a dilution 127 of 1:160, it was significantly associated with higher ANA titers (p= 0.02), and this trend remained 128 when analyzing the COVID⁺ and COVID⁻ patients separately. IgG aCL positivity was also 129 significantly associated with anti-cytokine autoantibodies, both when analyzed for positive or 130 high-positive anti-cytokine titers (p=0.003 for both, adjusted for multiple comparisons); this was 131 not related to any particular anti-cytokine autoantibody, although anti-interferon-y, anti-IL10 132 and anti-IL-17f were the most prevalent (supplemental table 2). When analyzing the aCL IgG 133 positive according to their COVID-19 status, the COVID⁺ had significantly higher levels of anti-134 cytokine autoantibodies than the COVID⁻ (supplemental Table 3). Anti-CL IgG was not associated 135 with antigen-specific autoantibodies, including SLE and myositis-related autoantibodies (not 136 shown).

137

138 DISCUSSION

139 The key observation of this study is that patients with positive IgG aCL showed a trend toward 140 more severe disease regardless of whether they were COVID⁺ and COVID⁻. That is, while COVID⁺ 141 patients showed non-significant trends towards worse respiratory outcomes when compared to 142 COVID⁻, aCL status had an independent association with disease severity, and did not modulate 143 the outcomes differentially based on COVID status. The pathological significance of aCL 144 seropositivity is unclear since there were no major differences in platelet counts or thrombotic 145 events in the two cohorts. Others have reported a high prevalence of aCL autoantibodies among COVID⁺ patients, but these studies lacked contemporaneous COVID⁻ control groups of similar 146 disease severity⁵⁶¹⁶¹⁷. 147

148

149 Although aCL tended to associate with COVID⁺, they did not associate with the presence of other

antigen-specific autoantibodies, although they had a strong association with certain anti-

151 cytokine autoantibodies. Interestingly, some patients had positive IgG aCL serology on ICU

6

152 admission (Table 2) in the absence of another relevant comorbidity such as APS or SLE 153 (supplementary table 1). These observations suggest that aCL positivity in the setting of acute 154 severe respiratory illness may be a marker of a unique phenotype with variable temporal 155 expression of aCL and anti-cytokine antibodies. The temporal dynamic is evidenced by the 156 relatively long timeframe from symptom onset to ICU admission to the development of IgG aCL 157 (Table 3). Our findings highlight the importance of longitudinal monitoring of acutely ill patients. 158 It seems plausible that disparate conclusions in the literature with respect to the significance of 159 APLAs in COVID-19 may relate to arbitrary sampling times and lack of longitudinal follow up in 160 the setting of dynamic inflammatory diseases.

161

162 While some reports have included lupus anticoagulant (LAC) in their analyses, we did not 163 because LAC is known to be an unreliable biomarker in severe illnesses where, C-reactive protein, anti-coagulant use and other factors confound its detection^{18 19}. In this study, we used 164 165 the anti-PS/PT test regarded by some as a surrogate for LAC (reviewed in³). However, only one patient developed anti-PS/PT 5-7 days after admission. Further, our observation that no patient 166 167 had antibodies to β 2-GP1 (an APS criteria antibody) or to domain 1 β 2-GPI (reportedly higher 168 specificity for APS) argues against the presence of APS in our cohort. In a study of 37 COVID+ 169 acute respiratory disease versus 31 pre-pandemic (not contemporaneous) acute respiratory 170 disease controls using a sample collected within 48 hours of admission, Frapard, et al. reported 171 that 37 COVID patients exhibited more thrombotic events as compared to 31 pre-pandemic 172 controls but the occurrence of APLA in the two groups was similar ²⁰. Using APLA assays similar 173 to ours, Borghi, et al. reported a low prevalence of APLA in COVID⁺ sera, where the most 174 common target was IgG β 2-GP1 (15.6%)¹⁷. In addition, the primary β 2GP1 antibody targets were in domains 2-4 which are less specific for APS¹⁷. In agreement with our study, Bertin *et al.*¹² and 175 176 Borghi *et al.*¹⁷ concluded that APLA were not associated with major thrombotic events.

177

The main limitation of our study is the small sample size. The strengths of our study include its prospective, contemporaneous COVID⁻ cohort with similar severity of disease. Importantly, we tested a broad APLA serological panel longitudinally, providing a more robust assessment of its true prevalence and incidence than in other reported studies; this is particularly relevant for such acutely ill patients with dynamic clinical courses. Finally, our use of an extensive serological panel allowed us to better characterize the broad phenotype associated with aCL.

7

184 KEY MESSAGES

185	What i	s already known about this subject?
186	•	COVID-19 is associated with coagulopathy and high morbidity and mortality.
187	•	COVID-19 shares some of these clinical features with anti-phospholipid syndrome.
188	•	Reports of an association of anti-phospholipid antibodies with high risk COVID-19 have
189		yielded disparate conclusions, but they lacked longitudinal follow up and control groups
190		of similar severity.
191		
192	What	does this study add?
193	•	Anti-phospholipid syndrome serology assessed longitudinally was predominantly
194		anticardiolipin IgG autoantibodies, in 48% of patients.
195	•	Anticardiolipin serology was associated with worse disease severity in both COVID-19
196		positive and negative patients.
197		
198	How n	night this impact on clinical practice or future developments?
199	•	The use of anti-phospholipid antibodies tests in the COVID-19 clinical setting needs to
200		be taken in context; whereas they are associated with more serve disease, they do not
201		discriminate between COVID-19 positive and negative patients.

202 DECLARATIONS

- 203 Ethics approval and consent to participate
- This research was approved by Research Ethics Boards at St Michael's Hospital and
- 205 performed in accordance with the Helsinki Declaration of 1975 as revised in 2013.
- 206 Consent for publication
- 207 Not applicable
- 208 Availability of data and materials
- The datasets used and/or analysed during the current study are available from the
- 210 corresponding author on reasonable request.
- 211 Competing interests
- MJF is the Director of MitogenDx. MJF is a consultant for and received speaking honoraria
- from Inova Diagnostics Inc (San Diego, CA) and Werfen International (Barcelona, Spain). All
- the other authors have no disclosures to declare.
- 215 Funding
- St Michael's Hospital Foundation, internal competitive grant to AB and CDS.
- Autoantibody testing was provided as a gift in kind by MitogenDx (Calgary, AB, Canada)
- 218 Authors' contributions
- This report is part of the COLOBILI study (Coronavirus longitudinal biomarkers in lung injury).
- AB and CDS are principal investigators; MJF, RR and AS are collaborators/co-investigators
 and UT is the research lead.
- RR, MJF, UT, and CDS conceived of the study; MJF, UT and RR wrote the manuscript drafts;
- AS, AB and CDS provided critique and technical guidance; UT performed the data analysis
- and creation of the figures. All authors edited the manuscript, through to the final version,
- read and approved the final submission.
- 226 Acknowledgements
- The authors acknowledge the technical assistance of Haiyan Hou, Meifeng Zhang and Emily
- 228 Walker in the MitogenDx Laboratory at the University of Calgary. We thank Marlene Santos,
- 229 Gyan Sadhu, Imrana Khalid, and Sebastian Duncan, the research coordinators at St Michael's
- Hospital Critical Care Research Unit. We are grateful to patients and families that have
- 231 generously consented to the study.
- 232 Study registration
- 233 NCT04747782 clinicaltrials.gov

234 Patient and Public Involvement

235	•	Patients and public were not involved in the design of the study. During the initial phases of
236		the study, we obtained feedback from the patients and their substitute decision makers.
237		Their concerns, questions and preferences were incorporated into improved processes for
238		consent and collection of biological samples. The consent forms have checkboxes with
239		optional aspects of the study, to accommodate different patient preferences. The results of
240		the study will be disseminated in lay versions by St. Michael's Hospital public relations and
241		communications departments for the benefit of the public.
242		

244		References
245		
246 247 248 249	1	Sevim E, Zisa D, Andrade D, Sciascia S, Pengo V, Tektonidou MG et al. Characteristics of Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. <i>Arthritis Care Res (Hoboken)</i> 2020; Online ahead of print:-doi: 10.1002/acr.24468.
250 251 252 253	2	Barbhaiya M, Zuily S, Ahmadzadeh Y, Amigo MC, Avcin T, Bertolaccini ML et al. Development of New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care Res</i> <i>(Hoboken</i>) 2020; Online ahead of print:-doi: 10.1002/acr.24520.
254 255 256 257	3	Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti- prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. <i>Thromb</i> <i>Haemost</i> 2014; 111:354-364.
258 259 260	4	Noordermeer T, Molhoek JE, Schutgens REG, Sebastian SAE, Drost-Verhoef S, van Wesel ACW et al. Anti-β2-glycoprotein I and anti-prothrombin antibodies cause lupus anticoagulant through different mechanisms of action. <i>J Thromb Haemost</i> 2021.
261 262 263	5	Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. <i>Sci Transl Med</i> 2020; 12(570):3876-doi: 10.1126/scitranslmed.abd3876.
264 265 266	6	El HG, Taher AT, Jawad A, Uthman I. COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association? <i>Clin Med Insights Arthritis Musculoskelet Disord</i> 2020; 13:1-8. doi: 10.1177/1179544120978667.
267 268 269	7	Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. <i>Br J Haematol</i> 2020; 189:846-847.
270 271 272 273	8	Fan BE, Ng J, Chan SSW, Christopher D, Tso ACY, Ling LM et al. COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis. <i>J Thromb Thrombolysis</i> 2020; On line ahead of print. Oct 24:10-02318.
274 275 276	9	Anka AU, Tahir MI, Abubakar SD, Alsabbagh M, Zian Z, Hamedifar H et al. Coronavirus Disease 2019 (COVID-19): An Overview of the Immunopathology, Serological Diagnosis and Management. <i>Scand J Immunol</i> 2020;e12998.
277 278 279 280	10	Pineton de Chambrun M, Frere C, Miyara M, Amoura Z, Martin-Toutain I, Mathian A et al. High Frequency of Antiphospholipid Antibodies in Critically-ill COVID-19 Patients: a Link with Hypercoagulability? <i>J Intern Med</i> 2020; Online ahead of print. Jun 12.:-doi: 10.1111/joim.13126.

- Showers CR, Nuovo GJ, Lakhanpal A, Siegel CH, Aizer J, Elreda L et al. A Covid-19 Patient
 with Complement-Mediated Coagulopathy and Severe Thrombosis. *Pathobiology* 2020;
 2:1-9. doi: 10.1159/000512503.
- Bertin D, Brodovitch A, Beziane A, Hug S, Bouamri A, Mege JL et al. Anti-cardiolipin IgG
 autoantibodies are an independent risk factor of COVID-19 severity. *Arthritis Rheumatol* 2020; 72(11):1953-1955. doi: 10.1002/art.41409.
- Mendoza-Pinto C, Garcia-Carrasco M, Cervera R. Role of Infectious Diseases in the
 Antiphospholipid Syndrome (Including Its Catastrophic Variant). *Curr Rheumatol Rep* 2018;
 20:62-0773.
- Connell NT, Battinelli EM, Connors JM. Coagulopathy of COVID-19 and antiphospholipid
 antibodies. *J Thromb Haemost* 2020; 10.1111:jth.14893.-doi: 10.1111/jth.14893.
- Radic M, Pattanaik D. Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome.
 Front Immunol 2018; 9:969.
- Tang N. Response to "Lupus anticoagulant is frequent in patients with Covid-19". *J Thromb Haemost* 2020;10.
- Borghi MO, Beltagy A, Garrafa E, Curreli D, Cecchini G, Bodio C et al. Anti-Phospholipid
 Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid
 Syndrome. *Front Immunol* 2020; 11:584241-doi: 10.3389/fimmu.2020.584241.
- 299 18 Gooding R, Myers B, Salta S. Lupus Anticoagulant in Patients with Covid-19. *N Engl J Med* 2020; 383:1893-doi: 10.1056/NEJMc2027508.
- Gkrouzman E, Barbhaiya M, Erkan D, Lockshin MD. A Reality Check on Antiphospholipid
 Antibodies in COVID-19-Associated Coagulopathy. *Arthritis Rheumatol* 2020; Online ahead
 of print:-doi: 10.1002/art.41472.
- Frapard T, Hue S, Rial C, de PN, Mekontso DA. Antiphospholipid antibodies and thrombosis
 in patients with COVID-19. *Arthritis Rheumatol* 2020; Online ahead of print. Dec 31.:-doi:
 10.1002/art.41634.
- 307
- 308
- 309

	Cohort	All	COVID ⁺	
	N	42	22	20
Age	Mean (Cl)	58.2 (62.7-54.1)	60.9 (66.6-55.3)	55.7 (62-48.7
Sex	% male	29/42 (69%)	17/22 (77%)	12/20 (60%)
Censored?	N (%)	5/42 (12%)	4/22 (18%)	1/20 (5%)
Number of days before censoring	Mean (CI)	39.4 (59.4-19.4)	44.3 (66.2-22.3)	20 (NA)
Days from symptom onset to ICU	Mean (CI)	6 (8.3-3.7)	7.5 (9.9-5.2)	4.2 (8.5-0)
APACHE II on ICU admission	Mean (CI)	25.3 (27.6-22.9)	23.7 (27-20.4)	27 (30.5-23.5
Mean of SOFA score for 1st 3 days	Mean (CI)	9.6 (10.7-8.5)	9.3 (11-7.7)	9.9 (11.6-8.3)
Mean of SOFA score for 1st 7 days	Mean (CI)	8.9 (10.1-7.8)	9.1 (11-7.3)	8.7 (10.3-7.2)
ICU days (censored)	Mean (CI)	14.1 (17.3-10.8)	14.2 (20.5-7.8)	14 (16.9-11.1
Death in ICU	N (%)	13/42 (31%)	7/22 (32%)	6/20 (30%)
Mechanical ventilation days (censored)	Mean (Cl)	14.4 (18.9-10)	16.8 (25.1-8.6)	11.8 (14.9-8.7
Total days of ventilation rescue measures	Mean (Cl)	2.9 (4.3-1.4)	4.4 (7-1.8)	1.2 (2-0.4)
Therapeutic anticoagulation used	N (%)	8/42 (19%)	3/22 (14%)	5/20 (25%)
Mean platelet count	Mean (Cl)	239 (269-209)	264 (313-214)	212 (245-179
Mean platelet to neutrophil ratio	Mean (Cl)	35.2 (42-28.4)	38.7 (48.4-29)	31.4 (41.6-21.
aCL IgG	N (%)	20/42 (48%)	13/22 (59%)	7/20 (35%)
aCL IgM	N (%)	9/42 (21%)	7/22 (32%)	2/20 (10%)
Anti-β2GPI IgG	N (%)	0	0	0
Anti-β2GPI IgM	N (%)	0	0	0
Anti-domain 1 β2GP1 IgG	N (%)	0	0	0
Anti-PS/PT IgG	N (%)	0	0	0
Anti-PS/PT IgM	N (%)	1/42 (2%)	1/22 (5%)	0

310 Table 1: Patient Demographic, Clinical and Autoantibody Status

311

312 <u>Abbreviations:</u> aCL, anticardiolipin; APACHE, Acute Physiology and Chronic Health Evaluation

313 (score); β2GP1, beta 2 glycoprotein I; ICU, intensive care unit; PS/PT, phosphatidyl

314 serine/prothrombin complex; SOFA, sequential organ failure assessment (score).

315

316 Legend: The data was censored on May 31, 2020. Days from symptom onset were self-reported

317 by the patients or their representatives. The SOFA score was performed daily for all patients; the

13

318 average was calculated for the first 3 and 7 days in the ICU for each patient, and the mean of 319 those averages are reported. For patients that underwent tracheostomy, mechanical ventilation 320 days are counted until successfully weaned from ventilatory support for 24 hrs. Rescue measures included use of paralytics, proning and inhaled NO (counted additively if more than 321 322 one intervention used in the same day). The clinical outcomes were measured for up to 3 323 months. All the serologies were tested longitudinally and are reported for the first 10 days from 324 admission to the ICU (for standardization among patients). There was no statistically significant difference between COVID⁺ and COVID⁻ patients for all variables, using ANOVA for continuous 325 variables and Fisher's exact test for categorical variables at α =0.05, followed by the false 326 327 discovery rate at q=0.05.

328

329 Table 2: Development of aCL IgG and IgM over time

Co	ohort	aCL detected on admission	aCL developed within 10 days	Late appearing aCL (after 10 days)
aCL lgG	COVID ⁺	4	9	2
positive	COVID	3	4	
aCL IgM	COVID ⁺	1	6	2
positive	COVID	1	1	1

330 **Abbreviations:** aCL, anti-cardiolipin antibodies.

331 Legend: late aCL was not included in the statistical analyses to avoid survival and availability

bias, and is shown here for qualitative assessment.

333

14

335 Table 3: Association between aCL IgG and disease severity, platelet counts and need for

336 anticoagulation

	Cohort	All	aCL IgG positive	aCL IgG negative
	Ν	42	20	22
Age	Mean (CI)	58.2 (62.7-54.1)	55.9 (62.9-49)	60.7 (66.4-55)
Sex	% male	29/42 (69%)	13/20 (65%)	16/22 (73%)
Days from symptom onset to ICU	Mean (CI)	6 (8.3-3.7)	8.7 (12.8-4.6)	3.4 (5.4-1.5)
APACHE II on ICU admission	Mean (CI)	25.3 (27.6-22.9)	25.7 (28.5-22.9)	24.9 (28.8-20.9)
Mean of SOFA score for 1st 3 days	Mean (CI)	9.6 (10.7-8.5)	10.6 (12.2-9.1)	8.7 (10.3-7)
Mean of SOFA score for 1st 7 days	Mean (CI)	8.9 (10.1-7.8)	10 (11.7-8.4)	8 (9.5-6.4)
ICU days (censored)	Mean (CI)	14.1 (17.3-10.8)	16.6 (21.9-11.3)	12.1 (16.5-7.6)
Death in ICU	N (%)	13/42 (31%)	8/20 (40%)	5/22 (23%)
Mechanical ventilation days (censored)	Mean (CI)	14.4 (18.9-10)	18.2 (25.5-10.8)	11.1 (16.4-5.7)
Total days of ventilation rescue measures	Mean (CI)	2.9 (4.3-1.4)	3.6 (5.6-1.5)	2.3 (4.4-0.1)
Therapeutic anticoagulation used	N (%)	8	4/20 (20%)	4/22 (18%)
Mean platelet count	Mean (CI)	239 (269-209)	268 (321-216)	212 (246-179)
Mean platelet to neutrophil ratio	Mean (CI)	35.2 (42-28.4)	34.8 (45.2-24.3)	35.6 (45.4-28.9)

337

338 <u>Abbreviations:</u> aCL, anticardiolipin; APACHE, Acute Physiology and Chronic Health Evaluation

339 (score); ICU, intensive care unit; SOFA, sequential organ failure assessment (score).

340

341 <u>Legend:</u> See Table 1 for details on the variables shown. There were no statistically significant

342 differences between aCL IgG positive and aCL IgG negative patients for all variables, using

ANOVA for continuous variables and Fisher's exact test for categorical variables at α =0.05,

followed by the false discovery rate at q=0.05.

345

346